[Form 4] CLOROX CO /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Marriner Kirsten, Executive Vice President and Chief Administrative Officer of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 7,689 shares of Clorox common stock at an average price of $124.85 per share, increasing her direct beneficial ownership to 33,994 shares. The filing is a single-person Form 4 signed by an attorney-in-fact on 09/18/2025. The report also discloses that the related Restricted Stock Units will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029.

Positive

• Insider acquisition: 7,689 shares purchased on 09/16/2025 at $124.85 per share
• Clear beneficial ownership: reporting person's direct holdings increased to 33,994 shares
• Explicit RSU vesting schedule: four equal installments on Oct 5, 2026, 2027, 2028, 2029
• Proper procedural filing: Form 4 filed by one reporting person and signed by attorney-in-fact

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider acquired 7,689 CLX shares at $124.85, modestly increasing direct ownership to 33,994 shares; transaction appears routine and non-material to valuation.

The transaction documents a purchase of 7,689 common shares by an executive officer, executed 09/16/2025. The acquisition price of $124.85 per share and the resulting direct ownership provide transparency on executive compensation conversion and stockholding. The disclosed RSU vesting schedule (annual 1/4 installments from 2026 through 2029) clarifies future share issuance timing tied to retention. Absent additional context—such as total outstanding shares or company-wide insider trends—this single trade is unlikely to be material on its own.

Corporate Governance Expert

TL;DR: Filing shows routine disclosure of an officer stock acquisition and RSU vesting schedule; governance procedures (Form 4, attorney-in-fact signature) were followed.

The report identifies the reporting person as an officer (EVP – Chief Administrative Officer) and indicates the Form 4 was filed by one reporting person and executed by an attorney-in-fact on 09/18/2025, consistent with procedural compliance. The explicit vesting timetable for the Restricted Stock Units provides clarity on future insider dilution timing. There are no disclosures of derivative transactions, dispositions, or unusual transfer mechanisms in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Marriner Kirsten

(Last) (First) (Middle)

1221 BROADWAY

(Street)

OAKLAND CA 94612-1888

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOROX CO /DE/ [ CLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Chief Admin Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		A(1)		7,689	A	$124.85	33,994	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units will vest in 4 equal installments - 1/4 on each of October 5, 2026, 2027, 2028 and 2029.

	By Jinho Joo, Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Marriner Kirsten report for CLX?

She reported an acquisition of 7,689 shares of Clorox common stock on 09/16/2025 at an average price of $124.85 per share.

How many CLX shares does Marriner Kirsten beneficially own after the reported transaction?

Following the transaction she beneficially owns 33,994 shares of Clorox common stock.

What is the vesting schedule for the Restricted Stock Units mentioned in the CLX Form 4?

The RSUs vest in four equal installments: one-quarter on each of October 5, 2026, 2027, 2028, and 2029.

When was the Form 4 filed for the CLX insider transaction?

The Form 4 was executed and filed on 09/18/2025 by an attorney-in-fact on behalf of the reporting person.

What is Marriner Kirsten's role at Clorox as stated in the filing?

She is listed as Executive Vice President – Chief Administrative Officer and a director is also indicated on the form.